Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.06.14	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
04.06.14	Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014 (Businesswire)
13.05.14	Ipsen SA: Ordinary Shareholders’ Meeting of 4 June 2014 (Businesswire)
13.05.14	Ipsen Announces a Step Forward in the Resupply of Increlex® in the U.S. (Businesswire)
07.05.14	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
30.04.14	Ipsen’s first quarter 2014 sales (Businesswire)
29.04.14	Ipsen: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to the Approval of the Ordinary Shareholders’ Meeting to Be Held on 4 June 2014 (Businesswire)
09.04.14	Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext (Businesswire)
20.03.14	Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement (Businesswire)
18.03.14	Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO) (Businesswire)
10.03.14	CORRECTING and REPLACING: Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
10.03.14	CORRECTING and REPLACING: Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
28.02.14	Ipsen's 2013 results and 2014 financial objectives (Businesswire)
07.02.14	Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer (Businesswire)
05.02.14	Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW1 (Businesswire)
28.01.14	Ipsen: sales in the fourth quarter and full year 2013 (Businesswire)
22.01.14	Ipsen Implements a New Governance in the United States to Prepare for the Launch of Somatuline® in Oncology (Businesswire)
17.01.14	Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint (Businesswire)
14.01.14	Ipsen and GW Pharmaceuticals plc Enter into Agreement for Ipsen to Promote and Distribute Sativex® in Latin America (Businesswire)
14.01.14	Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors (Businesswire)
13.01.14	Half-year IPSEN Liquidity Contract Statement Entered into With NATIXIS (Businesswire)
10.01.14	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
10.01.14	Jonathan Barnsley Joins Ipsen as Executive Vice President, Technical Operations (Businesswire)
23.12.13	Ipsen Announces Its Corporate Agenda for 2014 (Businesswire)
18.12.13	Ipsen and Mayoly Spindler enter into cross- promotion agreement for primary care activities in France (Businesswire)
18.12.13	Ipsen Prepares for the Resupply of Increlex® in Europe (Businesswire)
17.12.13	Ipsen Announces Positive Initial Results from the International Double-Blind Clinical Phase III Study of Dysport® in the Treatment of Adults Suffering from Upper Limb Spasticity (Businesswire)
12.12.13	Dominique Brard Joins Ipsen as Executive Vice President, Human Resources (Businesswire)
09.12.13	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.11.13	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.11.13	Ipsen Initiates a Share Buy-Back Program to Partially Cover Its Restricted Share Plans (Businesswire)
30.10.13	Ipsen: Sales in the Third Quarter and First Nine Months of 2013 (Businesswire)
09.10.13	Active Biotech Receives Tasquinimod Milestone Payment from Ipsen for 10TASQ10 Study (Businesswire)
07.10.13	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.10.13	PeptiDream and Ipsen Expand the Scope of Their Collaboration for Discovery of Peptide Drugs to Treat Serious Endocrinologic Disease (Businesswire)
02.10.13	Project of New Organization and New Composition of the Executive Committee to Accelerate the Implementation of Ipsen's Strategy (Businesswire)
28.09.13	Ipsen : results from CLARINET® Phase III clinical trial showed the antiproliferative effect of Somatuline® in the treatment of non-functioning GEP-NETs (Businesswire)
26.09.13	Ipsen to Relocate US R&D Activities to Cambridge, MA in 2014 (Businesswire)
26.09.13	Ipsen to Relocate US R&D Activities to Cambridge, MA in 2014 (Businesswire)
17.09.13	Ipsen announces positive top line results from phase III ELECT® study of Somatuline® in the control of symptoms in NET patients with a history of carcinoid syndrome (Businesswire)
09.09.13	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
30.08.13	Ipsen: Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013 (Businesswire)
30.08.13	Ipsen: 2013 Half-Year Results and Financial Objectives (Businesswire)
06.08.13	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
15.07.13	Ipsen Announce a Sponsored Research Agreement with Harvard Medical School to Discover Novel Engineered Botulinum Toxins for Serious Neurologic Diseases (Businesswire)
15.07.13	Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology (Businesswire)
11.07.13	Ipsen announces positive results from phase III CLARINET study of Somatuline® Autogel® 120mg in gastrointestinal and pancreatic neuroendocrine tumors ("GEP-NETs”)1 (Businesswire)
09.07.13	Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
09.07.13	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
07.02.13	Eziclen® / Izinova® a New Product for Bowel Cleansing Successfully Completed European Decentralised Registration Procedure (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten